NCT03739606 2020-12-17Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood CancerCity of Hope Medical CenterPhase 2 Withdrawn
NCT02718755 2018-06-26Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic MalignanciesM.D. Anderson Cancer CenterPhase 2 Withdrawn